| 000 | 01870 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518014528.0 | ||
| 264 | 0 | _c20200219 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1365-2141 | ||
| 024 | 7 |
_a10.1111/bjh.15741 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBöll, Boris | |
| 245 | 0 | 0 |
_aDoxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _c04 2019 |
||
| 300 |
_a42-52 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aDacarbazine _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHodgkin Disease _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLenalidomide _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVinblastine _xadministration & dosage |
| 700 | 1 | _aPlütschow, Annette | |
| 700 | 1 | _aBürkle, Carolin | |
| 700 | 1 | _aAtta, Johannes | |
| 700 | 1 | _aPfreundschuh, Michael | |
| 700 | 1 | _aFeuring-Buske, Michaela | |
| 700 | 1 | _aVogelhuber, Martin | |
| 700 | 1 | _aSökler, Martin | |
| 700 | 1 | _aEichenauer, Dennis A | |
| 700 | 1 | _aThielen, Indra | |
| 700 | 1 | _avon Tresckow, Bastian | |
| 700 | 1 | _aFuchs, Michael | |
| 700 | 1 | _aEngert, Andreas | |
| 700 | 1 | _aBorchmann, Peter | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 185 _gno. 1 _gp. 42-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjh.15741 _zAvailable from publisher's website |
| 999 |
_c29204218 _d29204218 |
||